Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
| العنوان: | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis |
|---|---|
| المؤلفون: | Francesca Di Rella, Paolo Chiodini, Carmen Pacilio, Giovanni Iodice, Michelino De Laurentiis, Daniela Cianniello, Matilde Pensabene, Giuseppina Fusco, Germira Di Gioia, Stefania Cocco, Vincenzo Di Lauro, Roberta Caputo, Francesco Nuzzo, Michela Piezzo, Maria Antonietta Riemma |
| المساهمون: | Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Di Gioia, G., Di Lauro, V., Di Rella, F., Fusco, G., Iodice, G., Nuzzo, F., Pacilio, C., Pensabene, M., De Laurentiis, M. |
| المصدر: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 21, Iss 6400, p 6400 (2020) |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Review, CDK4/6 inhibitor, lcsh:Chemistry, 0302 clinical medicine, Neoplasm Metastasis, subgroup analysis, lcsh:QH301-705.5, Spectroscopy, Hazard ratio, General Medicine, Prognosis, Metastatic breast cancer, Computer Science Applications, Survival Rate, 030220 oncology & carcinogenesis, Meta-analysis, epidemiology, Female, metastatic breast cancer, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, overall survival, therapies, Breast Neoplasms, Palbociclib, Hormone receptor, Catalysis, Inorganic Chemistry, Subgroup analysi, CDK4/6 inhibitors, 03 medical and health sciences, Internal medicine, medicine, cancer, Humans, Progression-free survival, Physical and Theoretical Chemistry, Protein Kinase Inhibitors, Molecular Biology, Survival analysis, Aromatase inhibitor, hormone therapy, business.industry, Organic Chemistry, hormone receptors, Cyclin-Dependent Kinase 4, Cancer, Cyclin-Dependent Kinase 6, medicine.disease, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, business |
| الوصف: | The introduction of CDK4/6 inhibitors in combination with endocrine therapy (ET) represents the most relevant advance in the management of hormone receptor (HR) positive, HER2-negative metastatic breast cancer over the last few years. This meta-analysis of randomized controlled trials (RCTs) is aimed to better characterize the efficacy of CDK4/6 inhibitors in some relevant subgroups and to test heterogeneity between different compounds with a particular focus on their ability to improve overall survival (OS). Pooled estimates of hazard ratios (HRs) were computed for progression-free survival (PFS), OS, and objective response rate (ORR) analysis in predefined subgroups to better understand treatment effect concerning specific patients’ characteristics. To estimate the absolute benefit in terms of PFS, pooled survival curves were generated by pooling the data of all trials. A total of eight RCTs were included. Adding a CDK4/6 inhibitor to ET is beneficial in terms of PFS, irrespective of the presence or not of visceral metastases, the number of metastatic sites, and the length of the treatment-free interval (TFI). The addition of CDK4/6 inhibitors produces a significant OS improvement, both in aromatase inhibitor (AI)-sensitive (HR 0.75, 95% CI) and AI-resistant patients (HR 0.77, 95% CI [0.67–0.89]). Pooled data from each single drug show that palbociclib remains the only class member not showing a statistically significant HR for OS (HR 0.83, 95% CI [0.68–1.02]). |
| تدمد: | 1422-0067 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9647a3fea841ea694dccb91b1ab03b14Test https://doi.org/10.3390/ijms21176400Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9647a3fea841ea694dccb91b1ab03b14 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14220067 |
|---|